Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
NCT01318902
Completed
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2020
Locations: Tufts Medical Center, Boston, Massachusetts +9 locations
Conditions: Light-Chain Amyloidosis
Register for Updates
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
NCT01222260
Completed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment, and to to estimate the partial hematologic response rate (PHR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2020
Locations: Tufts Medical Center, Boston, Massachusetts +5 locations
Conditions: AL Amyloidosis
Register for Updates
Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME
NCT04038125
Unknown
The objective of this study is to test the hypothesis that following the use of intravitreal dexamethasone implant for the treatment of DME, there will be an observable increase in the capillary density plexus as denoted by the quantitative assessment of the superficial capillary plexus on OCTA, as well as a decrease in size of the foveal avascular zone (FAZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2020
Locations: Retina Macula Specialists of Miami, LLC, North Miami Beach, Florida +1 locations
Conditions: Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Register for Updates
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
NCT02492750
Completed
This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma. Biological therapies, such as lenalidomide and anakinra, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Register for Updates
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
NCT01023308
Completed
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2020
Locations: Novartis Investigative Site, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Register for Updates
Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery
NCT03040011
Completed
To test the hypothesis that preoperative injections along the levator ani muscles and pudendal nerve with bupivacaine and dexamethasone improve pain control after vaginal apical reconstructive surgery. A three-arm, double-blinded, randomized controlled trial of a total of 75 women will be performed. The study population will be adult women (\>18 years of age) with uterovaginal or vaginal vault prolapse who have been scheduled for native tissue vaginal reconstructive surgery which includes an ap... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2020
Locations: Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Pelvic Organ Prolapse, Surgery, Postoperative Pain
Register for Updates
Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery
NCT01788475
Terminated
Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone prior vitrectomy. The sustained steroid levels may lead to improved central retinal thickness measurements and improved visual acuity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2020
Locations: Lahey Medical Center, One Essex Center Drive, Peabody, Massachusetts
Conditions: Diabetic Macular Edema
Register for Updates
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT01478581
Completed
The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2020
Locations: SITE-13, La Jolla, California +10 locations
Conditions: Multiple Myeloma
Register for Updates
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
NCT02928029
Terminated
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with bortezomib/dexamethasone for the Phase 2 portion of the study. The phase 2 part will be an international, phase 2, double-blind, randomized, placebo-c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2020
Locations: Pacific Oncology/Hematology Associates, Encinitas, California +6 locations
Conditions: Multiple Myeloma
Register for Updates
Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization
NCT02479620
Unknown
This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2020
Locations: Arkansas Heart Hospital, Little Rock, Arkansas +9 locations
Conditions: Chronic Limb Ischemia
Register for Updates
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT01049945
Completed
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2020
Locations: City of Hope, Duarte, California +4 locations
Conditions: Refractory Multiple Myeloma
Register for Updates
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00440726
Completed
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/07/2020
Locations: City of Hope, Duarte, California +23 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates